Delamanid
Deltyba (delamanid) is a small molecule pharmaceutical. Delamanid was first approved as Deltyba on 2014-04-27. It has been approved in Europe to treat multidrug-resistant tuberculosis.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| infections | D007239 |
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
27 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Multidrug-resistant tuberculosis | D018088 | EFO_0007381 | 1 | 6 | 6 | 1 | — | 14 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Pulmonary tuberculosis | D014397 | EFO_1000049 | A15 | — | 6 | 2 | — | — | 8 |
| Tuberculosis | D014376 | EFO_0000774 | A15-A19 | 1 | 5 | 2 | — | — | 7 |
| Extensively drug-resistant tuberculosis | D054908 | — | 1 | 1 | — | — | 2 | ||
| Bacterial infections | D001424 | A49 | — | — | 2 | — | — | 2 | |
| Gram-positive bacterial infections | D016908 | — | — | 1 | — | — | 1 | ||
| Mycobacterium infections | D009164 | A31.9 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hiv infections | D015658 | EFO_0000764 | B20 | 1 | 2 | — | — | 1 | 3 |
| Infections | D007239 | EFO_0000544 | — | 1 | — | — | — | 1 | |
| Hiv | D006678 | O98.7 | — | 1 | — | — | — | 1 |
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | DELAMANID |
| INN | delamanid |
| Description | Delamanid is a member of piperidines. |
| Classification | Small molecule |
| Drug class | mycolic acid inhibitors |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | C[C@]1(COc2ccc(N3CCC(Oc4ccc(OC(F)(F)F)cc4)CC3)cc2)Cn2cc([N+](=O)[O-])nc2O1 |
Identifiers
| PDB | — |
| CAS-ID | 681492-22-8 |
| RxCUI | — |
| ChEMBL ID | CHEMBL218650 |
| ChEBI ID | — |
| PubChem CID | 6480466 |
| DrugBank | DB11637 |
| UNII ID | 8OOT6M1PC7 (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 1,773 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
3,304 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more